Inmunoterapia en 1L del CPCNP: monoterapia y/o tratamiento combinado - page 4

1L NSCLC: Keynote 024

Reck M, et al. NEJM 2016

50%

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1,2,3 5,6,7,8,9,10,11,12,13,14,...42